Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation
Nature Communications2014Vol. 5(1), pp. 4177–4177
Citations Over TimeTop 10% of 2014 papers
Goro Sashida, Hironori Harada, Hirotaka Matsui, Motohiko Oshima, Makiko Yui, Yuka Harada, Satomi Tanaka, Makiko Mochizuki‐Kashio, Changshan Wang, Atsunori Saraya, Tomoya Muto, Yoshihiro Hayashi, Kotaro Suzuki, Hiroshi Nakajima, Toshiya Inaba, Haruhiko Koseki, Gang Huang, Toshio Kitamura, Atsushi Iwama
Related Papers
- → The noncanonical role of EZH2 in cancer(2021)92 cited
- → Targeting EZH2 as cancer therapy(2021)54 cited
- → Targeting EZH2 for Cancer Therapy: Progress and Perspective(2015)64 cited
- → Enhancer of zeste homolog 2: A potential target for tumor therapy(2011)39 cited
- → Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities(2022)8 cited